Jasmine Morales

Jasmine Morales

Auto-generated profile, based on publicly available information

Jasmine Morales

Hebert Wertheim School of Public Health, University of California, San Diego, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Health Affairs Scholar
Verified
Journal Article
Open access
PDF file
IHInmaculada Hernandez
Inmaculada Hernandez
STShangbin Tang
Shangbin Tang
JMJasmine Morales
Jasmine Morales
NGNico Gabriel
Nico Gabriel
NPNimish Patel
Nimish Patel
LBLucas A. Berenbrok
Lucas A. Berenbrok
Pharmacy accessibility is critical for equity in medication access and is jeopardized by pharmacy closures, which disproportionately affect independent pharmacies. We conducted a geographic information systems analysis to quantify how many individuals across the United States do not have optimal pharmacy access or solely rely on independent pharmacies for access. We generated service areas of pharmacies using OpenStreetMap data. For each individual in a 30% random sample of the 2020 RTI International US Household Synthetic Population (N = 90 778 132), we defined optimal pharmacy access as having a driving distance to the closest pharmacy ≤2 miles in urban counties, ≤5 miles in suburban counties, and ≤10 miles in rural counties. Individuals were then categorized according to their access to chain and independent pharmacies. Five percent of the sample or ∼15.1 million individuals nationwide relied on independent pharmacies for optimal access. Individuals relying on independent pharmacies for optimal access were more likely to live in rural areas, be sixty-five years or older, and belong to low-income households. Another 19.5% of individuals in the sample did not have optimal pharmacy access, which corresponds to 59.0 million individuals nationwide. Our findings demonstrate that independent pharmacies play a critical role in ensuring equity in pharmacy access.

23 May 2024 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
GAGiovanni E Appolon
Giovanni E Appolon
STShangbin Tang
Shangbin Tang
NGNico Gabriel
Nico Gabriel
JMJasmine Morales
Jasmine Morales
LBLucas A. Berenbrok
Lucas A. Berenbrok
IHInmaculada Hernandez
Inmaculada Hernandez

21 June 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
JMJasmine Morales
Jasmine Morales
NGNico Gabriel
Nico Gabriel
LNLoki Natarajan
Loki Natarajan
ALAndrea Z. LaCroix
Andrea Z. LaCroix
ASAladdin H. Shadyab
Aladdin H. Shadyab
FCfor the Powder for Pennies Collaboration
for the Powder for Pennies Collaboration
INTRODUCTION: Bumetanide, a loop diuretic, was identified as a candidate drug for repurposing for Alzheimer's disease (AD) based on its effects on transcriptomic apolipoprotein E signatures. Cross‐sectional analyses of electronic health records suggest that bumetanide is associated with decreased prevalence of AD; however, temporality between bumetanide exposure and AD development has not been established.METHODS: We evaluated Medicare claims data using Cox proportional hazards regression to evaluate the association between time‐dependent use of bumetanide and time to first AD diagnosis while controlling for patient characteristics. Multiple sensitivity analyses were conducted to test the robustness of the findings.RESULTS: We sampled 833,561 Medicare beneficiaries, 60.8% female, with mean (standard deviation) age of 70.4 (12). Bumetanide use was not significantly associated with AD risk (hazard ratio 1.05; 95% confidence interval, 0.99–1.10).DISCUSSION: Using a nationwide dataset and a retrospective cohort study design, we were not able to identify a time‐dependent effect of bumetanide lowering AD risk.Highlights: Bumetanide was identified as a candidate for repurposing for Alzheimer's disease (AD). We evaluated the association between bumetanide use and risk of AD. We used Medicare data and accounted for duration of bumetanide use. Bumetanide use was not significantly associated with risk of AD.

1 January 2026 in Journal for the Measurement of Physical Behaviour
Verified
Journal Article
Closed access
PDF file
JMJasmine Morales
Jasmine Morales
RZRong W. Zablocki
Rong W. Zablocki
SHSheri J. Hartman
Sheri J. Hartman
AKArun Kumar
Arun Kumar
AKAnimesh Kumar
Animesh Kumar
LNLoki Natarajan
Loki Natarajan
Background : Sedentary behavior (SB) is a risk factor for cardiometabolic disease. Existing cut points of hip-worn accelerometers to quantify SB underestimate sedentary bout durations by ignoring posture. To address this, we previously developed Convolutional Neural Network Hip Accelerometer Posture (CHAP), a deep-learning algorithm that predicts sitting and breaks from sitting. In this study, we applied CHAP to a randomized controlled trial to externally validate its accuracy for classifying sitting versus nonsitting and estimating intervention-related changes in SB. Methods : CHAP was applied to 30-Hz triaxial hip-worn ActiGraph-GT3X+ (AG) accelerometer data from free-living postmenopausal women who are overweight (≥55 years) in the Rise for Health RCT ( n = 406). CHAP-predicted SB accuracy (e.g., sensitivity) and daily pattern metrics (e.g., total sedentary time) were compared with a ground-truth device activPAL (AP) and standard cut-point method (AG100) at two timepoints for intervention arms—Healthy Living (control), Reduce Sitting, and Increase Transitions. Results : CHAP’s SB accuracy metrics were above 84.8%. Mean (standard error, p values) intervention effect estimates (mean change, intervention minus controls) from generalized estimating equation models for (a) total sedentary time were AP 65.1 min/day (16.2, p < .001), CHAP 38.2 min/day (15.4, p = .013), and AG100 0.28 min/day (13.9, p = .98; Reduce Sitting); (b) breaks from SB were AP 22/day (4.3, p < .001), CHAP 4/day (1.5, p = .003), and AG100 <1/day (2.1, p = .860; Increase Transitions). Conclusions : This study validated CHAP on an independent cohort. CHAP exhibited high prediction accuracy, and although less sensitive than AP, CHAP detected changes in SB more effectively than AG100. Thus, CHAP could make a strong contribution to SB intervention research.